TEV-56286が多系統萎縮症患者の治療に有効かどうかを検証する試験

基本情報

NCT ID

NCT06568237

ステータス

募集中

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

350

治験依頼者名

Teva Branded Pharmaceutical Products R&D, Inc.

概要

The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned study period per participant is 56 weeks including a screening period (up to 4 weeks), a 48-week double-blind treatment period, and a follow-up visit (approximately 4 weeks after the end of the double-blind treatment period). The study duration will be approximately 27 months.

対象疾患

介入

依頼者（Sponsor）

実施施設 (9)